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In the past decade, the HMG CoA reductase inhibitors
(HMGs) have revolutionized the treatment of hyperlipi-
demia. OBJECTIVES: The primary objective of this
study was to determine the relationship between the use
of HMGs and cardiovascular events in a diabetic hyper-
tensive population from a managed care perspective. The
secondary objective was to estimate any differences in
overall health care costs (e.g. hospitalizations, emergency
room visits, and pharmacy cost) between patients taking
HMGs and those who are not. METHODS: Retrospec-
tive computerized claims from a managed care organiza-
tion were analyzed (N  6739). Patients were included if
they had an ICD-9 diagnosis code for diabetes mellitus
and hypertension between 9/1/95 and 8/31/96. During
the identification period, patients who received an HMG
were included in the HMG group. Patients who never re-
ceived an HMG were included in the control group. All
patients were followed for 3 years. RESULTS: In a multi-
variate regression analysis controlling for potential con-
founding factors such as age, gender, benefit design, dis-
ease severity, and number of comorbidities, pharmacy
cost was higher in the HMG group (Beta  $1276, P 
0.0001). Use of the HMGs were associated with fewer
emergency room visits (Beta  0.387, P  0.0001) and
fewer inpatient days (Beta  19.7, P  0.0001). Logis-
tic regression controlling for the same factors showed pa-
tients in the HMG group were less likely to experience
death compared to the control group (odds ratio, 0.435;
95% confidence interval 0.365–0.517). CONCLUSION:
The HMGs are associated with fewer emergency room
visits, hospital days, and lowers the risk of death. The
higher pharmacy costs associated with the HMGs appears
to be offset by non-pharmacy cost savings.
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OBJECTIVE: To compare the impact of a diabetes dis-
ease management program (DDMP). METHODS: A pre/
post comparison was conducted to evaluate a DDMP
program in a V.A. nursing home. All diabetic patients re-
siding as of September 1998 (pre-DDMP) were compared
with those residing there in November 1999 (post-
DDMP). Data collection included age, sex, types of diet,
functional categories, weight, body mass index (BMI),
cholesterol, hemoglobin A1C (HA1C), urinalysis, eye
and foot exams, and antidiabetic drug therapies. RE-
SULTS: The pre-DDMP group had 31 males, mean age
76 years; post-DDMP group had 36 males, mean age 77
years. Eighteen men of the 36 men were in both the pre-
and post-DDMP groups; the remaining post-DDMP
group was admitted between study periods. Post-DDMP
group had a higher average BMI (P  0.01) and func-
tional category (P  04); attributed to the men admitted
after starting the DDMP. Number of patients achieving
HA1C semi-annual testing criteria was statistically greater
in the post-DDMP sample (30 pts (83%) vs. 13 pts
(42%), P  0.001). Mean HA1C results were better in
the post-DDMP sample (6.8% vs. 8.2%, P  0.01). Post
patients were more likely to have foot exams (P 
0.001). Changes in rates for urinalysis, cholesterol, and
eye exam were not statistically significant. Twelve pre-
DDMP patients were managed by diet alone; eleven in
the post group. More post patients were managed by two
or more drugs (P  0.04) which was attributed to men
admitted after starting the DDMP. CONCLUSION:
Post-DDMP group had more HAIC testing and better av-
erage results. A major observed change was in the in-
crease usage of drug combinations which might be re-
flected in the observed improvement of glycemic control.
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OBJECTIVES: The primary objective of this study was to
analyze the Medi-Cal 5% claims database in order to es-
timate the cost of illness for overactive bladder (OAB) to
the California Medicaid program. Secondary objectives
of this study were to describe patterns of care for patients
diagnosed with overactive bladder and to discover cost
offsets that could be achieved with drug treatment of
OAB. METHODS: A continuously enrolled (1996–1997)
cohort of overactive bladder patients was identified
based upon the presence of ICD-9 diagnosis codes and
drug claims in the database. All claims (physician, hospi-
tal, long term care, drug, and medical supply) for these
patients were analyzed to determine the quantity and cost
of services provided to patients with overactive bladder.
Additional analyses were performed to determine if there
were medical costs that could be offset by drug treatment
of overactive bladder. RESULTS: Claims for OAB were
analyzed for 97,160 unique patients. The prevalence of
OAB in this continuously enrolled population was
2.95%, significantly lower that the National Survey of
OAB estimate of 22%. The average direct costs per pa-
tient were $450 per year. Ninety-six percent of these
costs were for incontinence pads and supplies. Only 13%
of patients treated with oxybutynin continued therapy
for more than 3 months. Patients treated with drug ther-
apy alone or in combination with pads cost less to treat
than patients receiving pads alone. Urologists ordered
95% of diagnostic tests. When OAB was diagnosed and
treated, the number of claims and costs for comorbid uri-
nary tract infections and skin breakdown decreased.
CONCLUSION: Patients who receive drug treatment for
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OAB incur lower total costs for OAB management when
the cost of incontinence pads are considered.
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Basiliximab, daclizumab, and OKT3 are potent immuno-
suppressive induction agents used in kidney transplanta-
tion. All four agents have demonstrated statistically sig-
nificant reductions in the incidence of acute rejection
compared to standard therapy. However, the cost-effec-
tiveness of these induction agents has not been studied in
a uniform context or explored beyond a 1-year period
following transplantation. OBJECTIVE: The purpose of
this study is to estimate cost-effectiveness of basiliximab,
daclizumab, and OKT3 compared to standard therapy
over a 5-year period post transplantation using a societal
perspective. METHODS: A Markov model was con-
structed using four states (eventfree, rejection/graft sur-
vival, graft failure/dialysis, death) to reflect the different
clinical and economic states of transplant patients. The
costs examined included initial hospitalization cost, acute
rejection treatment cost, cost of graft failure and subse-
quent dialysis, cost of maintaining functional graft, and
drug cost for induction agents. The transition probabili-
ties and utilities were obtained from the randomized tri-
als and other literature. Costs were obtained from the US
Renal Data System Annual Report, the University Health-
System Consortium Pharmacy Database, the Red Book,
and literature. RESULTS: Average costs for the first year
post transplantation ranged from $58,052 to $78,153
and five-year total costs were estimated to be $154,806
(basiliximab), $155,712 (daclizumab), $181,113 (OKT3),
and $166,124 (standard therapy). Daclizumab ($48,665/
QALY) and basiliximab ($51,182/QALY) were more
cost-effective than standard therapy ($56,646/QALY) or
OKT3 ($60,391/QALY). CONCLUSION: Preliminary
results suggest that daclizumab and basiliximab are cost-
effective induction agents compared to standard therapy
when considered over a 5-year period following trans-
plantation. Extensive sensitivity analysis is planned to
test the robustness of this finding.
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The prevalence of peritoneal dialysis (PD) in the USA is
12%. PD is less costly and as effective as hemodialysis
(HD) for most patients. OBJECTIVE: To project savings
from a shift in modality distribution (MD) to home-
based therapies. METHOD: We developed a decision
model to assess the cost impact of changes in MD, mo-
dality cost (MC) or numbers of patients. IPD was ex-
cluded. Using 1999 USRDS data, we calculated MC and
applied patient numbers and MD. We previously sur-
veyed US nephrologists who opined optimal MD to max-
imize survival was: hospital HD 9.2%; community full-
care HD 33.9%; community self-care HD 13.8%; home
HD 12.1%; CAPD 17.5%; APD 14.3%; and IPD 1.5%.
To maximize cost-effectiveness the percentages changed
to 4.2, 24.9, 15.5, 16.5, 26.7, 12.4, and 1.0% respec-
tively. The estimated total dialysis spend, excluding epoi-
etin and non-ambulance transportation, was generated
and compared to the total cost using the “optimized”
MD. RESULTS: A total dialysis spend of $11.25 billion
was estimated using MD from the USRDS. The total sav-
ings and additional patients who could be treated at the
MD opined for maximum survival was $750 million
(6.7%) and 15,745, respectively; for maximum cost sav-
ings, $1.06 billion (9.5%) and 22,977. Survey limita-
tions, costing assumptions and modeling suggest caution
that the potential savings identified may or may not be
completely achievable. CONCLUSION: Effecting a change
in MD in accordance with what US nephrologists re-
ported to be acceptable could lead to substantial Medi-
care savings. Strategies to increase utilization of home
and self care therapies, which might include earlier refer-
ral and empowerment of patient choice, should be con-
sidered.
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OBJECTIVE: The objective of this study was to assess
the feasibility and usefulness of administering a quality of
life questionnaire within routine clinical practice with re-
nal patients. METHODS: This was a national 5 centre
study administering a disease-specific questionnaire, the
Renal Quality of Life Profile (RQLP). The RQLP was ad-
ministered by nurses to patients in addition to some de-
mographic and open-ended questions. Nurses reviewed
the completed questionnaire to identify potential areas
requiring discussion and contacted the patient to discuss.
RESULTS: The RQLP was administered to 140 patients:
24 predialysis, 12 home haemodialysis, 25 satellite hae-
modialysis, 21 hospital haemodialysis, 32 CAPD, and 26
transplant. 44% completed the questionnaire in the wait-
ing room, 22% in the consulting room, and 34% on dial-
ysis or at home. During questionnaire review, nurses felt
